[1] Nicholson A G, Tsao M S, Beasley M B, et al. The 2021 WHO classification of lung tumors:Impact of advances since 2015[J]. Thorac Oncol, 2022, 17(3):362-387.
[2] Masliah-Planchon J, Bièche I, Guinebretière J M, et al. SWI/SNF chromatin remodeling and human malignancies[J]. Annu Rev Pathol, 2015, 10:145-171.
[3] Wong A K, Shanahan F, Chen Y, et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines[J]. Cancer Res, 2000,60 (21):6171-6177.
[4] Dagogo-Jack I, Schrock A B, Kem M, et al. Clinicopathologic characteristics of BRG1-deficient NSCLC[J]. Thorac Oncol, 2020, 15(5):766-776.
[5] Schoenfeld A J, Bandlamudi C, Lavery J A, et al. The Genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancersmarca4 alterations in lung cancer[J]. Clin Cancer Res, 2020, 26(21): 5701-5708.
[6] Fernando T M, Piskol R, Bainer R, et al. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients[J]. Nat Commun, 2020, 11(1): 1-13.
[7] Alessi J V, Glass C, Ricciuti B, et al. Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC)[EB/OL].ASCO 2020: 9577.
[8] Le L F, Watson S, Pierron G, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas[J]. Nat Genet,2015, 47 (10): 1200-1205.
[9] Herpel E, Rieker R J, Dienemann H, et al. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens[J]. Ann Diagn Pathol, 2017,26:47-51.
[10] Bell E H, Chakraborty A R, Mo X, et al. SMARCA4/BRG1 Is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer[J]. Clin Cancer Res, 2016, 22(10):2396-2404.
[11] Hoadley K A, Yau C, Hinoue T, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer[J]. Cell, 2018, 173(2):291-304.
[12] Gupta M, Concepcion C P, Fahey C G, et al. BRG1 loss predisposes lung cancers to replicative stress and ATR dependency[J]. Cancer Res, 2020, 80(18):3841-3854.